Frontlight ResearchEarly access
Triple-negative breast cancer trials in France
43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peoplePhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Where
- Bron, Villejuif
- Age
- 18 years to 100 years
- People
- 162 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06562192 - Phase 2Taking peoplePembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
- Where
- Amiens Cedex 1, Avignon Cedex 9, Bayonne, Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex1, Clermont Ferrand Cedex 2, Dijon, Levallois-Perret, Limoges Cedex 1, Lyon, Marseille, Nantes Cedex 2, Nice Cedex 2, Nimes Cedex 9, Pau Cedex, Plérin, Pontoise, Quimper Cedex, Reims, Rennes Cedex, Saint-Grégoire, St Etienne Cedex 2, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 354 worldwide
- Run by
- UNICANCER
See details and how to joinNCT06078384 · EU 2023-504620-26-00 - No phaseTaking peopleEarly Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
- Where
- Avignon, Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier, Nîmes, Paris, Rennes, Saint-Cloud, Toulouse, Vandœuvre-lès-Nancy
- Age
- 18 years and over
- People
- 450
- Run by
- Institut Curie
See details and how to joinNCT06225505 - Phase 3Taking peoplePersonalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
- Where
- Amiens, Angers, Avignon, Besançon, Blois Cedex, Bordeaux, Bourg En Bresse, Brest, Caen, Caen Cedex 5, Chambray-lès-Tours, Cholet, Clermont Ferrand Cedex1, Compiègne, Dechy, Dijon, Epagny Metz-tessy, Grenoble, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, La Seyne-sur-Mer, Le Havre, Le Mans Cedex 9, Levallois-Perret, Limoges, Lyon, Marseille, MULHOUSE, Nantes Cedex 2, Nice Cedex 2, Nimes Cedex 9, Orleans Cedex 2, Paris, Pau, Périgueux, Plérin, Poitiers, Pontoise, Reims, Rennes Cedex, Rouen Cedex, Saint-Denis, Sainte-Foy-lès-Lyon, Saint-Herblain, Saint-Priest-en-Jarez, Soissons, Strasbourg, Tarbes, Thonon-les-Bains, Toulouse Cedex 3, Toulouse Cedex 9, Tours, Valence, Vandouvre Les Nancy, Villejuif
- Age
- 18 years and over
- People
- 2,454 worldwide
- Run by
- UNICANCER
See details and how to joinNCT06606730 · EU 2024-515787-31-00 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Bordeaux, Paris, Villejuif
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - No phaseTaking peoplePredicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer
- Where
- Rennes
- Age
- 18 years and over
- People
- 200
- Run by
- Center Eugene Marquis
See details and how to joinNCT07570524 - Phase 2Taking peopleEarly detection of triple negative breast cancer relapse (CUPCAKE)
- Where
- Avignon, Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier Cedex 5, Nimes Cedex 9, Paris, Paris Cedex 20, Rennes Cedex, Saint-Cloud, Toulouse, Vandouvre Les Nancy
- Age
- 18 years and over
- People
- 450
- Run by
- Institut Curie
See details and how to join2022-501562-22-01 - Phase 1/2CompletedA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Where
- Bayonne, Caen Cedex 5, Lille, Lyon, Marseille, Nice Cedex 2, Paris, St Herblain, Strasbourg, Villejuif
- Age
- 18 years and over
- People
- 182 worldwide
- Run by
- Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00 - No phaseNot yet taking people in FranceOmission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy
- Where
- Dijon, Paris, Saint-Cloud
- Age
- 18 years and over
- People
- 150
- Run by
- Institut Curie
See details and how to joinNCT07357948 - Phase 1Taking peopleProspectivE phase 0 pilot study, assessing potential prognostic and theranostic interest of 68Ga-PentiXafor PET-CT In metastatic triple neGative brEast caNCer patiEnts (EXIGENCE)
- Where
- Saint-Herblain Cedex
- Age
- 18 years and over
- People
- 12
- Run by
- Institut De Cancerologie De L Ouest
See details and how to join2024-517658-90-00 - No phaseTaking peopleEstablishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment
- Where
- Caen
- Age
- 18 years and over
- People
- 163
- Run by
- Centre Francois Baclesse
See details and how to joinNCT05404321 - Phase 2Not yet taking people in FrancePeritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer
- Where
- Reims
- Age
- 18 years and over
- People
- 760
- Run by
- Institut Jean-Godinot
See details and how to joinNCT07458204 - No phaseTaking peopleProspective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
- Where
- Bordeaux, Lille, Lyon, Paris, Saint-Cloud, Vandœuvre-lès-Nancy
- Age
- 18 years and over
- People
- 1,050
- Run by
- Institut Curie
See details and how to joinNCT03017573 - No phaseTaking peopleAssessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
- Where
- Saint-Herblain
- Age
- 18 years and over
- People
- 12
- Run by
- Institut Cancerologie de l'Ouest
See details and how to joinNCT06962163 - No phaseTaking peopleRadiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
- Where
- Rouen
- Age
- 18 years to 75 years
- People
- 115
- Run by
- Centre Henri Becquerel
See details and how to joinNCT06879704 - No phaseTaking people68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
- Where
- Antony, Paris, Saint-Cloud, Saint-Mandé, Suresnes
- Age
- 18 years and over
- People
- 60
- Run by
- Institut Curie
See details and how to joinNCT06349512 · EU 2023-507860-37-00 - Phase 2Taking peopleCapecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
- Where
- Amiens Cedex 1, Avignon Cedex 9, Bayonne, Besancon Cedex, Bordeaux, Brest Cedex 2, Caen Cedex 5, Dijon, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Lille, Limoges Cedex 1, Lyon, Marseille, Metz Cedex 03, Paris, Paris Cedex 13, Quint-Fonsegrives, Reims, Saint-Cloud, St Nazaire, Strasbourg, Toulouse Cedex 9, Tours, Vandouvre Les Nancy
- Age
- 18 years and over
- People
- 220
- Run by
- UNICANCER
See details and how to joinNCT05973864 · EU 2023-505291-30-01 - Phase 1/2Taking peopleA Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
- Where
- Villejuif
- Age
- 18 years and over
- People
- 50
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT06508216